Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 7/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | CDC25A | P30304 | 1/20 | 0.62 |
| ▸ | CDC25B | P30305 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792241 | 0.97 | MAPT (0.76) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL1791237 | 0.90 | TTR (0.76) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL1793147 | 0.90 | MAPT (0.76) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL1789659 | 0.90 | TTR (0.76) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL1792290 | 0.90 | SMN1; SMN2 (0.70) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL190100 | 0.90 | MEN1 (0.80) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL3135247 | 0.90 | MAPT (0.70) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL1790930 | 0.90 | CDC25A (0.77) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL15256408 | 0.90 | MAPT (0.73) | MAPTSMN1; SMN2MAPK1POLBGFER | |
| SCHEMBL1791643 | 0.89 | MAPT (0.76) | MAPTSMN1; SMN2MAPK1POLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | Atomwise Inc. | 2023-08-03 | — | — | US | disclosed |
| US-9949980-B2 | Drugs to prevent HPV infection | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150297602-A1 | DRUGS TO PREVENT HPV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20140128388-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8541415-B2 | Targeting an HIV-1 nef-host cell kinase complex | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110190241-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | UNIVERISTY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-08-04 | — | — | US | disclosed |
| US-20110165220-A1 | DRUGS TO PREVENT HPV INFECTION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2011-07-07 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165220-A1 | DRUGS TO PREVENT HPV INFECTION | VHL, PHF13, CDKN1A | MAPT 4500/4885SMN1; SMN2 3894/4885MAPK1 1445/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4580/4885SMN1; SMN2 4624/4885MAPK1 63/4885 |
| US-20230241074-A1 | INHIBITORS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | MAVS, PIGS, SARS1 | MAPT 4487/4885SMN1; SMN2 4762/4885MAPK1 2001/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4580/4885SMN1; SMN2 4624/4885MAPK1 63/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4606/4885SMN1; SMN2 4676/4885MAPK1 66/4885 |
| US-20110190241-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | HCK, DCK, NCK1 | MAPT 1585/4885SMN1; SMN2 3731/4885MAPK1 195/4885 |
| US-20150297602-A1 | DRUGS TO PREVENT HPV INFECTION | VHL, PHF13, CDKN1A | MAPT 4500/4885SMN1; SMN2 3894/4885MAPK1 1445/4885 |
| US-20140128388-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | HCK, DCK, NCK1 | MAPT 1549/4885SMN1; SMN2 3725/4885MAPK1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.